HuidaGene Therapeutics Gains FDA Clearance for First CRISPR/Cas13 RNA-Editing Therapy HG202 to Treat Macular Degeneration

Complete Genomics Unveils New Sequencing Innovations and Expanded DNBSEQ-T7 Applications at ASHG 2024

QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel Gains FDA Clearance, Accelerating CNS Infection Diagnosis

Tempus AI to Acquire Ambry Genetics for $600 Million, Expanding Genetic Testing Capabilities

Aiforia and Paige form strategic partnership to advance AI integration in pathology laboratories

CytoDyn Receives FDA Clearance to Begin Phase II Trial of Leronlimab for Colorectal Cancer

MGM Medical College in Indore Pioneers CAR T Cell Therapy for Blood Cancer Treatment in India’s Public Healthcare System

AbbVie and EvolveImmune Therapeutics Partner in New Collaboration and Licensing Agreement to Advance Next-Generation Cancer Biotherapeutics

Cardiff Oncology Publishes Phase 2 Trial Data on Second-Line Treatment for KRAS-Mutant mCRC in *Journal of Clinical Oncology*

Advanced Genomics APAC and Compass Bioinformatics Forge Strategic Alliance to Enhance Rare Disease and Cancer Diagnostics in APAC Region

Telo Genomics Expands Mayo Clinic Collaboration to Advance Multiple Myeloma Prognostic Testing

Daiichi Sankyo and AstraZeneca Launch Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations in Advanced Non-Small Cell Lung Cancer

FDA Approves Novartis Scemblix® for Newly Diagnosed CML, Showcasing Superior Efficacy and Improved Safety Profile

IDEAYA Biosciences Secures IND Clearance for IDE275 (GSK959) to Initiate Phase 1 Trial in MSI-High Solid Tumors

MGI Partners with OncoDNA to Enhance Precision Oncology with Compatible Genomic Solutions

Home
/
update
/
details

Advanced Genomics APAC and Compass Bioinformatics Forge Strategic Alliance to Enhance Rare Disease and Cancer Diagnostics in APAC Region

NextEdge Admin

31 Oct 2024

2 min 38 sec

Compass Bioinformatics,Rare Disease,Cancer Diagnostics

Advanced Genomics APAC has announced a strategic partnership with Compass Bioinformatics Inc., aiming to broaden the use of next-generation sequencing (NGS) technology for rare disease and cancer diagnostics across Japan, South Korea, Southeast Asia, and Australasia. This collaboration is set to drive market expansion and improve access to precision medicine across the APAC region.

Focusing on rare disease diagnostics, the partnership will integrate Advanced Genomics APAC's Cell3™ Target: Nexome Panel, designed for effective pathogenic variant capture, with Compass Bioinformatics' InheriNext® analytical software. Together, they provide a complete, streamlined diagnostic solution that spans from library preparation to high-precision data analysis, allowing for faster, more accurate diagnoses. The InheriNext® platform, which launched in 2020, has already facilitated over 3,500 rare disease diagnoses and received notable regulatory clearances, including U.S. FDA Class I Medical Device approval, Taiwan TFDA QMS certification, and ISO 13485 standards compliance.

This partnership is poised to significantly impact patients with rare diseases, who often face diagnostic delays of over six years, with genetic factors accounting for over 80% of cases. The collaboration’s combined technologies aim to reduce these delays, enhancing diagnostic efficiency across APAC healthcare institutions.

Andy Chang, General Manager of Advanced Genomics APAC, highlighted the partnership's potential to embed Nexome into APAC’s diagnostic landscape, with anticipated benefits for rare disease and cancer patients. Ping-Cheng Hsiung, General Manager of Compass Bioinformatics, emphasized their shared mission to advance genomic diagnostics, increasing both accuracy and efficiency. In the coming months, the partners plan to launch services and share results with healthcare providers across the region, contributing to advancements in diagnostics for rare diseases and oncology.